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The development and use of service guidance was one of a number
of important United Kingdom (UK) policy initiatives for cancer
services introduced over the last 15 years. These initiatives began
with the national programme to introduce breast screening in the
late 1980s. This was a carefully managed process supported by
additional resources. There were new guidelines, specific arrange-
ments for monitoring and evaluation, and ongoing quality
management. This well-organised approach to screen-detected
disease contrasted sharply with the absence of an equivalent
approach to symptomatic breast cancer patients. There was
evidence of considerable variability in symptomatic breast services
(Chouillet et al, 1994; Sainsbury et al, 1995; Richards et al, 1996)
and pressure to address this issue from professional communities
(British Breast Group, 1994) and patient groups. At the same time,
deeper anxieties were emerging about the performance of UK
cancer services. International comparisons suggested that the UK
did less well than many comparable countries (Sant et al, 1995,
1998). Public, professional and media concerns focused on the fact
that when potential cancer patients were referred to hospital, this
was not necessarily to a specialist in their particular cancer. Were
patients’ chances of a good outcome overdependent on their initial
hospital referral?
The challenge to look afresh at cancer care was taken up by the
Chief Medical Officers in England and Wales, and by their
counterparts in Scotland and Northern Ireland. This led to the
publication of a policy document generally known as the Calman-
Hine report (Department of Health, 1995) in 1995, with equivalents
in Scotland and Northern Ireland. The evidence supporting this
policy was later published in summary form (Selby et al, 1996).
This was the first ever national policy for the delivery of cancer
services in the UK. It offered a clear framework for the delivery of
good cancer care, which tried to put the patient at the heart of
policy. The issue of specialisation was tackled directly through
recommendations for the development of explicit multiprofes-
sional multidisciplinary clinical management arrangements. These
were to be available to all patients. Calman-Hine had a sustained
impact and has been a crucial policy initiative. The positive
reactions from many clinicians, the public and NHS organisations
to the recommendations implied widespread acceptance of the
need to deal with the weaknesses in UK cancer care. It was this
broadly based support for change, rather than any particularly
effective national strategy for implementation, that enabled action
to follow. The one exception was the crucial early decision to
commission disease-specific service guidance. This was to
complement the overall policy framework by providing detailed
recommendations for each of the main types of cancer. The first
cancer guidance (all are entitled ‘Improving Outcomes in y
Cancer’) covered breast cancer (Department of Health, 1996). The
exercise broke new ground, as there was no previous ‘working
model’ of national service guidance in the UK. The guidance
development process was rigorous and utilised systematic
evidence reviews together with the careful involvement of expert
opinion (Haward, 1998; Haward and Sheldon, 1999; Haward and
Eastwood, 2001). These were complex reports to produce and the
supporting evidence reviews are substantial pieces of work. Just as
these documents were a challenge to their developers, they posed
new questions for managers. The NHS had not previously been
faced with implementing such explicit and comprehensive
recommendations for the clinical organisation and delivery of
services for specific diseases.
The first guidance, for breast cancer, set out the nature and roles
expected of multidisciplinary breast cancer care teams. Core team
members were specified and each was to be a specialist in breast
cancer within their discipline. Each team had to have an adequate
caseload (4100 new cases per year) to maintain and develop its
expertise and justify the investment in bringing the team together.
The simple aim was that all potential breast cancer patients should
be assessed, diagnosed and managed by such a team. Similar
guidance followed for colorectal and lung cancer. The first three
guidance documents recommended that services should be
based on local cancer units (Haward, 1995) rather than being
concentrated at specialised cancer centres (except for radio-
therapy, thoracic and liver surgery), thus laying the groundwork
for a coherent approach to service delivery for common
cancers. The process of establishing new teams for these common
cancers addressed another key recommendation in Calman-
Hine to expand access to nonsurgical oncologists (clinical
and medical oncology) at cancer unit level, with more chemother-
apy for these diseases being delivered locally (Haward and
Amir, 2000). In England, modest additional funds were al-
located to support implementation of each guidance document
in turn, promoting dialogue between health organisations and
clinicians about priorities (NHS Executive, 1997). This investment
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Subsequent guidance documents were far more complex as they
each dealt with services for groups of cancers rather than single
diseases (e.g. gynaecological malignancies). They covered issues
common to the group of cancers, such as access and diagnosis, as
well as individual site-specific matters (such as staging or
treatment). Particular attention was given to integrating care
between different parts of the service. The longstanding problems
of optimal service configuration were addressed with greater
clarity than previous national policies, delineating the respective
clinical roles of local units and specialised centres for the diseases
in question. They recommended centralisation of specific clinical
services such as radical surgical procedures and defined the
necessary scale of activity for specialist teams to work effectively
and efficiently.
Thus, the guidance addressed a key concern about UK cancer
care, the fact that complex clinical work was often very thinly
spread, with many patients being treated by individual clinicians
or in hospitals managing few cases of any particular type over a 12
month period. While the published evidence that this practice was
undesirable is of variable quality, and the issue undoubtedly
arouses controversy, results from recent systematic reviews
suggest that greater specialisation and higher caseloads lead to
better outcomes, particularly for high morbidity or mortality
interventions (Hillner et al, 2000; Institute of Medicine, 2001;
Teisberg et al, 2001; Halm et al, 2002).
Although it was widely acknowledged that services for
intermediate and rare types of cancer needed to be delivered
more consistently, with patterns of service delivery reflecting
caseload and the complexities of diagnosis and treatment, there
was little prior consensus on the way forward. The guidance
provided an invaluable ‘route map’ for important reconfigurations
in service delivery. It has shifted the NHS debate (or the absence of
debate) from what to do, towards active discussion about how best
to implement the required changes. Major shifts in patterns of
service delivery are inevitably complicated to bring about, and can
face professional and institutional resistance to move away from
the status quo. Progress in the UK has been hampered by genuine
manpower and logistic difficulties in bringing together the
requisite people and facilities to operate specialist services on a
larger scale. Most key disciplines remain in short supply. It was
appreciated at the outset that time would be needed for cancer
networks to build up the necessary clinical resources, including
expertise across the full range of clinical disciplines, supported by
the necessary facilities. To help implementation, the guidance
included an economic analysis of the cost implications of these
complex service configuration issues, which demonstrated that
costs were very variable and dependent on the prior state of local
services in the particular field (Ward et al, 2000). This emphasised
the need for implementation to be dealt with at local level, with
priorities based on the actual situation in each place. Resources to
support the changes have proved hard to pull together despite the
identification nationally of ‘new money’ for investment in cancer
services in the National Cancer Plan for England (Department of
Health, 2000). This problem has been compounded by the number
of health organisations with control over resources in the areas
covered by many cancer networks.
Although the Calman-Hine report encouraged the concept of
networks linking primary care, community services, local hospitals
(cancer units) and specialist cancer centres, it offered no practical
advice on organisational issues. As a result, cancer networks
developed slowly, and were frequently seen by managers as purely
clinical in scope. Indeed, it took five more years before concerns
about the uneven implementation of cancer policy found coherent
expression. The key initiatives in England (with similar but not
identical initiatives in the rest of the UK) included the appoint-
ment of a National Cancer Director, the publication of a National
Cancer Plan and the development of Cancer Service Standards
(Department of Health, 2000; NHS Executive, 2000). These
standards formed the basis for peer review of cancer services
across England, a process that is to be repeated at intervals. Many
individual standards were taken directly from the ‘Improving
Outcomes’ guidance.
The amount of organisational change affecting the NHS has
made it harder for statutory bodies to work together effectively to
achieve long-term changes to clinical services. Cancer networks
(mandatory rather than statutory organisations) have therefore
grown in importance backed by explicit national support for their
roles in leading the development of cancer services. This has led
them becoming better-resourced organisations despite ambiguities
about their organisational status. Successive guidance documents
have laid increasing stress on the responsibilities of cancer
networks to oversee complex service changes. Their success is
crucial if long-term change is to be achieved, yet the control and
allocation of resources still requires them to work with and
through multiple statutory health organisations in their areas.
A further government initiative to expand the scope of cancer
networks was the establishment of an English National Cancer
Research Network (NCRN) in 2001. This was preceded by an
equivalent exercise in Wales and subsequently mirrored by similar
initiatives in Scotland and Northern Ireland. The NCRN has
significant resources to promote and support higher rates of entry
of cancer patients into clinical trials and other well-designed
studies. Cancer networks have received additional investment to
enable them to form an associated research network for this
purpose. While the primary goal was to expand clinical cancer
research, it was also intended to improve cancer care through the
more widespread adoption of modern protocols of care. The
formation of research networks stimulated clinical collaboration
across the hospitals within each cancer network.
The adoption and use of documented clinical policies such as
protocols and clinical guidelines can be an important means of
achieving consistent standards of care. In Scotland, the long-
running series of SIGN clinical guidelines includes guidelines for a
number of types of cancer (http://www.sign.ac.uk; Scottish Cancer
Therapy Network, 1997). There has been no equivalent initiative in
England and Wales until the establishment of the National
Institute for Clinical Excellence with a specific role in the
production of clinical guidelines. This body now has responsibility
for the ‘Improving Outcomes’ series of service guidance, with new
titles and updates in preparation. However, there are as yet, no
published national clinical guidelines on cancer from NICE
although these are planned for the management of genetic risk
in familial breast cancer and for lung cancer. NICE have
established a new National Collaborating Centre for Cancer, which
will begin a long-term programme of clinical guideline develop-
ment in cancer from April 2003. Around the time of the Calman-
Hine report, limited encouragement was given to professional
bodies with interests in cancer to publish clinical guidelines and a
number have done so successfully, although there was no
consistency in the methodologies used (British Association
of Surgical Oncology, 1995; Royal College of Surgeons of England
& Association of Coloproctology of Great Britain and Ireland,
1996).
At local level, there has been interest in using clinical guidelines
to bring clinical networks together and provide a rational basis for
audit. While evidence-based service guidance has provided the
route map for improving the organisation of cancer care, it has not
been complemented by an equally convincing approach to the
development and use of clinical guidelines, outside Scotland. It
seems self-evident that there must be opportunities for greater
cooperation and collaboration in the preparation and use of
clinical guidelines within the UK and between the UK and other
countries with similar interests. Systematic evidence reviews and
reputable processes of guideline development are expensive, and
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investments could be utilised more effectively if guideline
developments covered larger clinical communities.
So what conclusions can be drawn about the roles of evidence-
based service guidance and clinical guidelines in policies for
improving cancer care in the UK? The cancer policy initiatives in
the mid-1990s have been of immense importance. They led to a
continuous process of cancer services development based on a
specialist multidisciplinary model for the delivery of services. The
‘Improving Outcomes Guidance’ played a crucial role, building on
the success of the Calman-Hine policy, but extending it by
specifying how services for particular cancer sites should be
delivered. Reconfiguration of services for the intermediate or rarer
cancers would not have been approached consistently – if at all,
had evidence-based guidance not been developed, and remains
dependant on the framework of national service guidance. The
potential of authoritative clinical guidelines to promote consistent
clinical policies and practice has not been sufficiently exploited
outside Scotland.
Implementation of cancer policy was handled differently in the
various UK countries, and was inconsistent within England. Policy
implementation as well as policy development must be addressed
coherently if any strategy is to succeed in changing services in fact
rather than in theory. Access to resources to support desired
changes has been a critical issue and tensions remain between the
governments’ disease-specific developmental priorities – aiming
for long-term improvements in the way complex clinical services
are delivered (and ultimately in the outcomes they achieve) and
other competing priorities set for the NHS. The devolution of
control over resources to large numbers of statutory organisations
makes it harder to coordinate developments requiring investment
in secondary- and tertiary-level hospital services.
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